Abstract 274P
Background
Index tumors are recognized as the most aggressive prostate tumors; however, their clinical implications remain unclear. This study aimed to investigate the occurrence of index tumor localization based on zonal origin and explore the impact of these locations on the prognosis after radical prostatectomy among patients with negative surgical margins.
Methods
In this retrospective, single-center study, a cohort of 1,109 consecutive patients who underwent radical prostatectomy was analyzed. The index tumor was defined as the largest tumor within the prostate gland. Localization was determined using McNeal's zonal origin classification on whole-mount sections. Kaplan-Meier survival curves were employed to assess biochemical recurrence (BCR)-free survival. Univariate and multivariate Cox proportional hazards analyses were conducted to identify predictive factors for early BCR (within 1 year).
Results
Among the 621 patients with negative surgical margins and no adjuvant therapy, index tumors were localized in the transitional zone in 191 patients (30.8%), the peripheral zone in 399 patients (64.3%), and the central zone in 31 patients (5.0%). A total of 22 patients (3.5%) experienced early BCR, and 70 patients (11.2%) experienced overall BCR during a median follow-up period of 61.7 months. Based on index tumor location, the early BCR-free rates were 99.5%, 95.7%, and 83.3% for the transitional, peripheral, and central zones, respectively. Multivariate analysis identified the index tumor in the central zone as an independent predictor of early BCR with negative surgical margins following radical prostatectomy, followed by the pathological grade of the prostatectomy specimen, index tumor in the peripheral zone, and a high prostate-specific antigen level.
Conclusions
This study examined the significance of index tumor location among patients with negative surgical margins after radical prostatectomy. Notably, index tumors situated in the central zone, although infrequent, emerged as the most robust predictors of early BCR. These findings may prompt urologists and patients to reconsider their therapeutic strategies for prostate cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract